el-Ani D, Jacobson K A, Shainberg A
Otto Meyerhoff Drug Receptor Center, Department of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.
Biochem Pharmacol. 1994 Aug 17;48(4):727-35. doi: 10.1016/0006-2952(94)90050-7.
Adenosine receptors were studied on heart cells grown in cultures by the radioligand binding technique. We used the hydrophilic A1 adenosine receptor radioligand [3H]-8-cyclopentyl-1,3-dipropylxanthine ([3H]CPX), to monitor the level of the receptors on intact cardiocytes. The binding showed high affinity (Kd = 0.13 nM) and the number of [3H]CPX binding sites (Bmax) was 23.1 fmol/dish (21 fmol/mg protein). The Ki of the agonists R-N6-(2-phenylisopropyl)-adenosine (R-PIA) and S-N6-(2-phenylisopropyl)-adenosine (S-PIA), and of the antagonists CPX and theophylline were 3.57, 49.0, 1.63 and 4880 nM, respectively. The number of adenosine receptors was very low during the first days in cultures (5 fmol/dish) and increased gradually until it reached a plateau on days 8-10. Treatment with norepinephrine or isoproterenol which accelerated the rate of contractions, induced up regulation of the receptors. Bmax increased 2-3-fold by application of norepinephrine for 4 days, while receptor affinity to the radioligand was unaffected. Lactate dehydrogenase (LDH) and creatine kinase (CK) activity increased only by 22 and 38%, respectively. Similarly, 3 days treatment with triiodothyronine (T3, 10(-8) M), which also accelerated heart rate, increased the number of adenosine receptors by 56% without a significant change in the affinity of the receptors to [3H]CPX. Carbamylcholine (5 x 10(-6) M), which reduced the rate of heart contractions, caused 26% down regulation while the affinity of the receptors remained unchanged. It is concluded that there is a linkage between the rate of cardiac contractions and the level of adenosine receptors. Thus, the level of adenosine receptors may respond to drug-induced chronic changes in cardiac contractile activity so as to restore conditions to normal (basal) contractions.
采用放射性配体结合技术,对培养的心脏细胞上的腺苷受体进行了研究。我们使用亲水性A1腺苷受体放射性配体[3H]-8-环戊基-1,3-二丙基黄嘌呤([3H]CPX),来监测完整心肌细胞上受体的水平。结合显示出高亲和力(Kd = 0.13 nM),[3H]CPX结合位点的数量(Bmax)为23.1 fmol/培养皿(21 fmol/mg蛋白质)。激动剂R-N6-(2-苯异丙基)-腺苷(R-PIA)和S-N6-(2-苯异丙基)-腺苷(S-PIA)以及拮抗剂CPX和茶碱的Ki分别为3.57、49.0、1.63和4880 nM。培养最初几天腺苷受体的数量非常低(5 fmol/培养皿),并逐渐增加,直到第8至10天达到平台期。用去甲肾上腺素或异丙肾上腺素处理可加速收缩速率,诱导受体上调。应用去甲肾上腺素4天,Bmax增加2至3倍,而受体对放射性配体的亲和力未受影响。乳酸脱氢酶(LDH)和肌酸激酶(CK)活性仅分别增加22%和38%。同样,用三碘甲状腺原氨酸(T3,10^(-8) M)处理3天,这也会加速心率,使腺苷受体数量增加56%,而受体对[3H]CPX的亲和力没有显著变化。卡巴胆碱(5×10^(-6) M)可降低心脏收缩速率,导致26%的下调,而受体的亲和力保持不变。结论是心脏收缩速率与腺苷受体水平之间存在联系。因此,腺苷受体水平可能对药物诱导的心脏收缩活动的慢性变化做出反应,从而将情况恢复到正常(基础)收缩状态。